← All trials
NCT05321979
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 7, 2022
- Primary completion
- May 31, 2023
- Completion date
- Oct 31, 2023
- First posted
- Apr 11, 2022
- Last posted
- Apr 11, 2022
- Enrollment
- 300
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medy-ToxLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.